Using experimental systems and patient material we study the immune system with a specific interest related to inflammation, autoimmune disease and cancer.
A major part of the different projects in the lab involves using CRISPR-based custom screens as a discovery platform to understand complex biological processes and to identify novel drug targets.
Currently several projects in the lab relates to our interest in signaling downstream of the IL-4 receptor (IL-4R). The basis for this interest was the unexpected finding that the expression of the IL-4R on myeloid cells is essential for the activity of a drug (IVIG) used to treat patients with autoimmune disease, and that this receptor is highly regulated during inflammation (Anthony et al, 2011, Nature and Wermeling et al, 2013, PNAS).
The Wermeling Laboratory is located at the Center for Molecular Medicine (CMM), Karolinska University Hospital, Solna, Sweden. The group is part of the Devision of Rheumatology, Department of Medicine, Karolinska Institutet, Solna.
More than 200h teaching in several KI programs, including Medical, Optometry, Biomedicine, and various master programs and PhD courses.
Academic honours, awards and prizes
Wenner-Gren fellow, 2010
Ingvar Carlsson Award (SSF), 2013
Senior Investigator Award from Swedish Cancer Foundation, 2022